RLYB114
RLYB114
- Stage
- Preclinical
- Indication
- Complement-driven ophthalmic diseases
- Approach
- C5-targeted Affibody® molecule conjugated to polyethylene glycol (PEG) to extend half-life
- Mode of Administration
- Intravitreal administration
Ophthalmic Diseases
Complement dysregulation has been shown to be a driver of ocular inflammation, contributing to vision loss in diseases such as age-related macular degeneration (AMD), where significant unmet medical needs remain.